John's questions to Recursion Pharmaceuticals Inc (RXRX) leadership • Q2 2025
Question
John asked how Recursion is making bold, transformative investments in its vision, similar to xAI's heavy investment in compute, and what next-level initiatives are planned.
Answer
Co-Founder and CEO Chris Gibson highlighted that Recursion is already a top global company in terms of compute scale in biopharma. He described the company's ambition to build a "virtual cell," a comprehensive computational model of biology, by integrating multi-layered data from patient genomics, pathway maps, and protein modeling. He also mentioned the Frontier Research Group, which explores high-risk areas like causal AI and the use of AI agents to automate drug discovery, with successful projects moving into the main Recursion OS.